Application of IGF-1 in the diagnosis and treatment of pituitary tumor

doi:10.3877/cma.j.issn.2095-9141.2020.03.012

Abstract

Abstract:

Insulin-like growth factor-1 (IGF-1) and its receptor are components of the insulin-like growth factor system and play an important role in the development and evolution of tumors such as nervous system, respiratory system and digestive system. Through the intervention of the relationship between IGF-1 and its receptor and tumor evolution, it can provide help for the clinical diagnosis and treatment of tumors. Pituitary tumors are relatively common intracranial tumors. Studies have found that IGF-1 is expressed in pituitary tumors. This article describes the expression and application of IGF-1 and tumors in pituitary tumor.

Key words: Insulin-like growth factor-1, Tumor, Pituitary tumor, Acromegaly

Zhaowei Xu, Rui Bai, Hubin Duan, Yimin Fan. Application of IGF-1 in the diagnosis and treatment of pituitary tumor[J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2020, 06(03): 183-186.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsjcswkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9141.2020.03.012

https://zhsjcswkdzzz.cma-cmc.com.cn/EN/Y2020/V06/I03/183

References 41

[1]	何仲琴.胰岛素样生长因子1在老年非小细胞肺癌患者外周血中的改变及临床意义[J].临床和实验医学杂志, 2016, 15(14): 1401-1404.
[2]	邹晓岚,叶茸茸,王洋,等.胰岛素样生长因子-1及其受体在肿瘤中的研究进展[J].重庆医学, 2018, 47(18): 2474-2476, 2479.
[3]	顾玉彬.肾癌组织中转录因子E2相关因子2和膜岛素样生长因子-1的表达[J].肿瘤基础与临床, 2016, 29(3): 198-200.
[4]	曹友红,许春芳.胰岛素样生长因子-1受体在恶性肿瘤中的研究进展[J].现代肿瘤医学, 2015, 23(5): 706-709.
[5]	章菊,叶书来,董行,等.血清IGF-Ⅰ和IGFPB-3检测在不同类型脑肿瘤中的应用[J].临床输血与检验, 2017, 19(5): 475-478.
[6]	李毅芳,李凌,蔡燕芝,等.奥曲肽序贯溴隐亭对GH型垂体瘤伴海绵窦侵袭的疗效[J].热带医学杂志, 2018, 18(7): 963-967.
[7]	Daughaday WH, Salmon WD Jr, Alexander F. Sulfation factor activity of sera from patients with pituitary disorders[J]. J Clin Endocrinol Metab, 1959, 19(7): 743-758.
[8]	Troncoso R, Ibarra C, Vicencio JM, et al. New insights into IGF-1 signaling in the heart[J]. Trends Endocrinol Metab, 2014, 25(3): 128-137.
[9]	Losa M, Bollerslev J. Pros and cons in endocrine practice: pre-surgical treatment with somatostatin analogues in acromegaly[J]. Endocrine, 2016, 52(3): 451-457.
[10]	Wolfe A, Divall S, Wu S. The regulation of reproductive neuroendocrine function by insulin and insulin-like growth factor-1 (IGF-1)[J]. Front Neuroendocrinol, 2014, 35(4): 558-572.
[11]	Caban M, Owczarek K, Chojnacka K, et al. Overview of polyphenols and polyphenol-rich extracts as modulators of IGF-1, IGF-1R, and IGFBP expression in cancer diseases[J]. J Funct Foods, 2019, 52: 389-407.
[12]	Murekatete B, Shokoohmand A, McGovern J, et al. Targeting insulin-like growth factor-I and extracellular matrix interactions in melanoma progression[J]. Sci Rep, 2018, 8(1): 583.
[13]	Wang Y, Wang W, Li D, et al. IGF-1 alleviates NMDA-induced excitotoxicity in cultured hippocampal neurons against autophagy via the NR2B/PI3K-AKT-mTOR pathway[J]. J Cell Physiol, 2014, 229(11): 1618-1629.
[14]	李旭,姚智.不同类型脑肿瘤患者血清胰岛素样生长因子-Ⅰ检测的临床意义[J].中国全科医学, 2011, 14(23): 2687-2688.
[15]	Giovannone B, Scaldaferri ML, Federici M, et al. Insulin receptor substrate (IRS) transduction system: distinct and overlapping signaling potential[J]. Diabetes Metab Res Rev, 2000, 16(6): 434-441.
[16]	Crino PB. The mTOR signalling cascade: paving new roads to cure neurological disease[J]. Nat Rev Neurol, 2016, 12(7): 379-392.
[17]	Zhou Y, Geng P, Liu Y, et al. Rotavirus-encoded virus-like small RNA triggers autophagy by targeting IGF1R via the PI3K/Akt/mTOR pathway[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(1): 60-68.
[18]	Tsai JL, Lee YM, Pan CY, et al. The novel VEGF121-VEGF165 fusion attenuates angiogenesis and drug resistance via targeting VEGFR2-HIF-1α-VEGF165/lon signaling through PI3K-AKT-mTOR pathway[J]. Curr Cancer Drug Targets, 2016, 16(3): 275-286.
[19]	Dobolyi A, Lékó AH. The insulin-like growth factor-1 system in the adult mammalian brain and its implications in central maternal adaptation[J]. Front Neuroendocrinol, 2019, 52: 181-194.
[20]	Day PF, Loto MG, Glerean M, et al. Incidence and prevalence of clinically relevant pituitary adenomas: retrospective cohort study in a health management organization in Buenos Aires, Argentina[J]. Arch Endocrinol Metab, 2016, 60(6): 554-561.
[21]	Hirohata T, Ishii Y, Matsuno A. Treatment of pituitary carcinomas and atypical pituitary adenomas: a review[J]. Neurol Med Chir (Tokyo), 2014, 54(12): 966-973.
[22]	蒋霞,蒋晶,虞培娟,等.不同类型脑肿瘤患者血清胰岛素样生长因子对比研究[J].中国实用神经疾病杂志, 2016, 19(17): 66-67.
[23]	Werner H, LeRoith D. Insulin and insulin-like growth factor receptors in the brain: physiological and pathological aspects[J]. Eur Neuropsychopharmacol, 2014, 24(12): 1947-1953.
[24]	Bake S, Selvamani A, Cherry J, et al. Blood brain barrier and neuroinflammation are critical targets of IGF-1-mediated neuroprotection in stroke for middle-aged female rats[J]. PLoS One, 2014, 9(3): e91427.
[25]	薛胜祥.不同类型脑肿瘤患者血清IGF-Ⅰ表达水平的研究[J].中华神经外科疾病研究杂志, 2014, 13(6): 544.
[26]	马瑞敏,贾子琪,康熙雄,等.血清生长激素与胰岛素样生长因子1水平对脑部肿瘤鉴别诊断价值的探讨[J].检验医学与临床, 2017, 14(23): 3435-3437.
[27]	D’Ercole AJ, Stiles AD, Underwood LE. Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action[J]. Proc Natl Acad Sci U S A, 1984, 81(3): 935-939.
[28]	Knosp E, Steiner E, Kitz K, et al. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings[J]. Neurosurgery, 1993, 33(4): 610-617.
[29]	Nishioka H, Fukuhara N, Horiguchi K, et al. Aggressive transsphenoidal resection of tumors invading the cavernous sinus in patients with acromegaly: predictive factors, strategies, and outcomes[J]. J Neurosurg, 2014, 121(3): 505-510.
[30]	王志明,蒲九君,孙彦龙,等. IGF-1和IGF-1R在无功能性垂体腺瘤中的表达及意义[J].第三军医大学学报, 2015, 37(13): 1367-1372.
[31]	Sanchez-Tejada L, Sanchez-Ortiga R, Moreno-Perez O, et al. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness[J]. Endocrinol Nutr, 2013, 60(7): 358-367.
[32]	Wang H, Tang C, Na M, et al. miR-422a inhibits glioma poliferation and invasion by targeting IGF1 and IGF1R[J]. Oncol Res, 2017, 25(2): 187-194.
[33]	Gallagher EJ, LeRoith D. World leaders describe the latest in IGF research[J]. J Mol Endocrinol, 2018, 61(1): E1-E3.
[34]	Yamashita S, Weiss M, Melmed S. Insulin-like growth factor I regulates growth hormone secretion and messenger ribonucleic acid levels in human pituitary tumor cells[J]. J Clin Endocrinol Metab, 1986, 63(3): 730-735.
[35]	Argente J, Chowen JA, Perez-Jurado LA, et al. One level up: abnormal proteolytic regulation of IGF activity plays a role in human pathophysiology[J]. EMBO Mol Med, 2017, 9(10): 1338-1345.
[36]	Iguchi H, Nishina T, Nogami N, et al. Phase I dose-escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-573, a dual IGF-I/II neutralizing antibody, in Japanese patients with advanced solid tumours[J]. Invest New Drugs, 2015, 33(1): 194-200.
[37]	Lee HS, Cho HJ, Kwon GT, et al. Kaempferol downregulates insulin-like growth factor-I receptor and ErbB3 signaling in HT-29 human colon cancer cells[J]. J Cancer Prev, 2014, 19(3): 161-169.
[38]	Nagaraj K, Lapkina-Gendler L, Sarfstein R, et al. Identification of thioredoxin-interacting protein (TXNIP) as a downstream target for IGF1[J]. Proc Natl Acad Sci USA, 2018, 115(5): 1045-1050.
[39]	Sanchez-Lopez E, Flashner-Abramson E, Shalapour S, et al. Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling[J]. Oncogene, 2016, 35(20): 2634-2644.
[40]	中华医学会神经外科学分会,中国垂体腺瘤协作组,中华医学会内分泌学分会.中国肢端肥大症诊治指南(2013)[J].中华神经外科杂志, 2013, 29(10): 975-979.
[41]	中国垂体腺瘤协作组.中国垂体腺瘤外科治疗专家共识[J].中华医学杂志, 2015, 95(5): 324-329.

Please choose a citation manager

Content to export